AbbVie Inc. — Form 8-K
Filed October 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
AbbVie reported Q3 2026 adjusted diluted EPS of $3.82 (>100% increase YoY) on net revenues of $17.404B (+10.5% operational). The company raised full-year 2026 adjusted EPS guidance from $13.76–$13.96 to $13.95–$13.99 and completed acquisition of Apogee Therapeutics, adding IL-13 and IL-13/TSLP assets to immunology pipeline. Dividend increased 5.2% to $1.82/share effective February 2027.
Why this rating
Strong Q3 operational growth (10.5%) and guidance raise are positive; Apogee acquisition (~$1.3B IPR&D charge YTD) is modest relative to $325B market cap, deepening pipeline but not transformational for company scale.
See more from October 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.